Zejula (niraparib) capsules - GSKpro
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling . Revised: 5/2021 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE. 1.1 First-Line Maintenance Treatment of Advanced Ovarian Cancer 1.2 Maintenance Treatment of Recurrent Ovarian Cancer 1.3 Treatment of Advanced Ovarian …
Download Zejula (niraparib) capsules - GSKpro
Information
Domain:
Source:
Link to this page:
Documents from same domain
BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and ...
gskpro.com• The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.2) ... whenever solution and container permit. Do not use the vaccine if either ... BOOSTRIX is a suspension for injection available in 0.5-mL single-dose vials and prefilled
JEMPERLI (dostarlimab-gxly) injection
gskpro.com• Complications of allogeneic hematopoietic stem cell transplantation (HSCT): Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1–blocking antibody. (5.3) • Embryo-fetal toxicity: Can cause fetal harm. Advise females of
LAMICTAL (lamotrigine) Tablets LAMICTAL (lamotrigine ...
gskpro.comcould cause serious arrhythmias and/or death in patients with certain underlying cardiac disorders or arrhythmias. Any expected or observed benefit of LAMICTAL in an individual patient with clinically important structural or functional heart disease must be carefully weighed against the risk for serious arrythmias and/or death for that patient .
NUCALA (mepolizumab) for injection NUCALA (mepolizumab ...
gskpro.com17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. _____ 2 . FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . 1.1 Maintenance Treatment of Severe Asthma . NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged ...
ZENTEL® Albendazol 200 mg Tabletas
gskpro.comZENTEL® está contraindicado durante el embarazo, y durante un mes antes de la concepción. Con el fin de evitar la administración de albendazol durante el embarazo precoz, las mujeres en edad fértil deben iniciar el tratamiento durante la primera semana de la menstruación o después de una prueba de embarazo negativa. 4 . RD N°22158-2015 2da.
ZYRTEC ORAL DROPS 10 mg/ml ZYRTEC ORAL SOLUTION 1 …
gskpro.comCetirizine dihydrochloride, a metabolite of hydroxyzine, is an anti-allergic agent, with a histamine H 1 receptor antagonism devoid of any significant anticholinergic and antiserotonin effects as demonstrated in experimental and clinical pharmacology.
ゼビュディ点滴静注 調製・投与方法のご案内
gskpro.com5）Fadini GP, et al. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020. 6）Zheng Z, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.
GSKPro for Healthcare Professionals
gskpro.comPriming VENTOLIN HFA is essential to ensure appropriate albuterol content in each actuation. Prime VENTOLIN HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped. To prime VENTOLIN HFA, release 4 sprays into the air away f rom the face, shaking well before each spray.
Guía para el uso racional de antibióticos
gskpro.comO’Neil J.Tackling drug-resistant infections globally: fi nal report and recommendations. Chaired by Jim O` Neil.[Internet] Mayo 2016. [Último acceso: junio 2018].
INFECCIONES DEL TRACTO URINARIO (ITU)
gskpro.comStaphylococcus saprophyticus en mujeres jóvenes sanas. 6 Resistencia antimicrobiana. Definición y epidemiología Etiología Manifestaciones clínicas Diagnóstico Tratamiento INFECCIONES DEL TRACTO URINARIO (ITU) MANIFESTACIONES CLÍNICAS Cistitis aguda simple en mujeres
Related documents
IMVEXXY. Undiagnosed abnormal genital bleeding
www.imvexxy.comIMVEXXY safely and effectively. See full prescribing information for IMVEXXY. Undiagnosed abnormal genital bleeding (IMVEXXY® (estradiol vaginal inserts) Initial U.S. Approval: 1975 WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA See full prescribing information for complete boxed warning.
HIGHLIGHTS OF PRESCRIBING INFORMATION ——— …
www.novo-pi.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 3/2020 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions 2.2 General Dosing Instructions 2.3 Starting Dose in Insulin Naïve Patients
HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter or …
docs.boehringer-ingelheim.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 10/2020 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Idiopathic Pulmonary Fibrosis 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease
ZEPOSIA U.S. Prescribing Information
packageinserts.bms.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPOSIA safely and effectively. See full prescribing information for ZEPOSIA. ZEPOSIA® (ozanimod) capsules, for oral use Initial U.S. Approval: 2020-----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.novartis.usWhen given with KISQALI, refer to the Full Prescribing Information for the recommended dose of the aromatase inhibitor being used. When given with KISQALI, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant.
PIQRAY (alpelisib) tablets, for oral use (Grade ≤ 2 ...
www.novartis.usSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection 2.2 Dosage and Administration 2.3 Dose Modifications for Adverse Reactions 3 DOSAGE FORMS AND …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.pi.amgen.comSee full prescribing information for complete boxed warning. -Chronic Kidney Disease: • -----In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1). ...
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.us.astellas.comHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use MYRBETRIQ ® /MYRBETRIQ ® GRANULES safely and effectively. See full prescribing information for MYRBETRIQ /MYRBETRIQ GRANULES. o. not chew, divide. MYRBETRIQ (mirabegron extended-release tablets), for oral use .
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
www.xhance.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 04/2021 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE . 2 DOSAGE AND ADMINISTRATION . 2.1 Nasal Polyps . 2.2 Administration Information . 3 DOSAGE FORMS AND STRENGTHS . 4 CONTRAINDICATIONS . 5 …